"Escape" Phenomenon of the Antihypertensive Therapy Efficacy

NCT ID: NCT05436730

Last Updated: 2022-06-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

165 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-09-29

Study Completion Date

2025-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A little attention is paid to the AHT efficacy escaping problem, which can be explained by the AHT correction simplicity and rapid achievement of the target BP level. Nevertheless, modern statistic data on the effective AH treatment described above let us assume that AHT correction is either totally absent or is untimely in case of the "escape" phenomenon development. This could be one of the main reasons for the high prevalence of ineffective AH treatment. The aim of this study is to determine AHT efficacy "escape" phenomenon timeline and its predictors in hypertensive patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

"Escape" Phenomenon of the Antihypertensive Therapy Efficacy

Men and women aged 18-90 years with arterial hypertension grade 1-3, stage I-II and initially achieved target BP levels while taking 2-3-component AHT.

Ambulatory blood pressure measurement device

Intervention Type DEVICE

Assessment of the 24-h blood pressure profile

Sphygmocor

Intervention Type DEVICE

Assessment of the arterial stiffness

VaSera-VS

Intervention Type DEVICE

Assessment of the arterial stiffness

Somnocheck

Intervention Type DEVICE

Assessment of the sleep breath disturbances

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ambulatory blood pressure measurement device

Assessment of the 24-h blood pressure profile

Intervention Type DEVICE

Sphygmocor

Assessment of the arterial stiffness

Intervention Type DEVICE

VaSera-VS

Assessment of the arterial stiffness

Intervention Type DEVICE

Somnocheck

Assessment of the sleep breath disturbances

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BpLab

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Arterial hypertension (AH) grade 1-3, stage I-II
* High compliance during the follow-up period (≥ 85%)
* Initially achieved target office BP levels while taking 2-3-component AHT

Exclusion Criteria

* Secondary AH
* Resistant AH,
* AH III stage,
* PAP- therapy,
* type 2 diabetes mellitus,
* pregnancy
* history of low adherence to treatment
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Federal State Budgetary Institution NATIONAL MEDICAL RESEARCH CENTRE OF CARDIOLOGY NAMED AFTER ACADE

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mikhailova Oksana

Dr., clinical reseacher

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Oksana Mikhailova

Moscow, , Russia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Russia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

115061870017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Spermidine Anti-Hypertension Study
NCT04405388 UNKNOWN PHASE3